Zecotek News

Zecotek Raises Additional $2,000,000; Engages Caliber Capital Partners
Monday April 2, 5:00 pm ET

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 2, 2007) - Zecotek Medical Systems Inc. (TSX VENTURE:ZMS - News; FRANKFURT:W1I - News) is pleased to announced that it has raised an additional $2,000,000 from the exercise of share purchase warrants and options. The Company has now raised an aggregate of $5.5 million through the $3.5 million non-brokered private placement completed in February 2007 and through the exercise of warrants and options.

Net proceeds from the funds raised will be used for working capital purposes and for projects presently underway at its Singapore operating facilities. The projects include initializing commercial production of the Zecotek's solid-state MAPD photo-detector, completion of a 32" commercial prototype of the 2D3D display, the transfer of production of the Company's new 456 and 488 nm lasers from its Moscow labs to its Singapore labs, and to initiate commercial production of the Company's high performance RFO vanadate laser crystals. Furthermore, Zecotek has established a new marketing and production team, based in Singapore, for the sales and marketing of its lasers and laser products.

Zecotek Medical Systems Inc. also announced today that it has retained the services of Caliber Capital Partners of Vancouver, to provide investor relations and capital market advisory services.

Commencing immediately, Caliber will develop and manage Zecotek's investor relations program for a term of twelve months to March 31, 2008. Services will continue on a monthly basis whereby either party may terminate the agreement upon tendering three months written notice. Caliber will receive a monthly retainer of $6,000, plus approved expenses.

About Caliber Capital Partners

Caliber Capital Partners is a British Columbia-based capital market advisory firm assisting emerging companies to achieve their growth potential, brand recognition and establish a fair market value within the financial marketplace. Caliber Capital has a history of providing strategic financial advice to emerging private and publicly traded companies and has established a reputation for dedication and excellence. Visit us at www.CaliberCapitalPartners.com.

About Zecotek

Zecotek Medical Systems (TSX VENTURE:ZMS - News; FRANKFURT:W1I - News) is a bio-photonics technology company developing high-performance crystals, photo detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders.

This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For additional information on Zecotek Medical Systems and our technologies please see our website at www.zecotekmed.com.

If you would like to receive news from Zecotek in the future, please email ir@zecotek.com and mention "ZMS News" in the subject heading or visit the corporate website at www.zecotekmed.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

 

Zecotek Subsidiary Acquires Product and Intellectual Property Assets of Two Laser Manufacturers
Thursday April 12, 5:00 pm ET

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 12, 2007) - Zecotek Medical Systems Inc. (TSX VENTURE:ZMS - News; FRANKFURT:W1I - News) today announced that Zecotek Laser Systems Pte. Ltd. has closed on the previously announced letter of intent to acquire product and intellectual property assets from Inversion Fiber Co. Ltd. (Inversion) and Tekhnoscan JS Company (Tekhnoscan). Under the terms of the Agreements, Zecotek Laser Systems has acquired exclusive rights to a complementary portfolio of laser products, additional production capability and a proven team of world-class engineers. Inversion and Tekhnoscan each receive a minority five percent share of Zecotek Laser Systems. Zecotek Laser Systems also receives ongoing revenues generated from the sale of current and future products in development, as well as future revenue generated by existing or future intellectual property which may be created under the joint venture. All other fixed assets and liabilities remain under current Russian ownership.

"We are delighted to bring Inversion and Tekhnoscan with their exceptional team of world class experts in design, development, production, and distribution of high value laser products under Zecotek's management," said Dr. F. A. Zerrouk, Chairman, President, and CEO of Zecotek Medical Systems. "Zecotek has taken ownership of a very competitive portfolio of cutting-edge laser technologies, products, and world class production facilities, and, perhaps more importantly, we now have the ability to bring to market Zecotek's own lasers currently in late stage development."

Zecotek has valued the acquired assets of each company at approximately US$5 million based on current and future revenue projections of the combined entity. Zecotec Laser Systems anticipates future growth through the product development, manufacturing, and distribution synergies of the three entities under a single management structure. The introduction of new products including Zecotek's 456 and 488-nm lasers for biomedical applications, and a line of new fiber lasers which have been developed in partnership with Inversion will also contribute to future growth.

Zecotek Medical Systems also announced that Dr. Sergey Babin, Director and CEO of Inversion Fiber, and Dr. Sergey Kobtsev, President/CEO and Founder of Tekhnoscan, will immediately join Zecotek Laser Systems' executive team.

Dr. Sergey Babin has been appointed Zecotek Laser Systems' Executive Vice President Development, Manufacture & Commercialization of Fiber Laser products. In 1993 Dr. Babin co-founded Inversion as a commercial laser centre within the Academy Town of Novosibirsk to develop a range of high-power fiber laser systems for research and industrial applications, and successfully introduced these into the domestic and international markets. He led a prominent laser lab and has authored well over one hundred scientific papers and holds numerous patents. Dr. Babin has been a member of OSA since 1996 and a member of IEEE/LEOS since 2001. In 2001 he was appointed to Russia's prestigious Board of National Experts in laser technologies.

Dr. Sergey Kobtsev has been appointed Zecotek Laser Systems' Executive Vice President Development, Manufacture & Commercialization of Solid State Lasers. Since 1983 he has headed Novosibirsk State University's Laser Systems Laboratory. He is the founder of Tekhnoscan JS Company which has developed and brought to market a wide range of proprietary laser products based on dye and Ti:Sapphire technology. Dr. Kobtsev has published more than a hundred scientific papers and has been awarded numerous inventor certificates. He has been a member of the Board of National Experts (Russia) since 1998, a member of the Russian Laser Association since 1996, the President of the Academ-Laser Association since 1996, and a member of OSA and IEEE.

About Inversion

Inversion Fiber Co. Ltd. develops and manufactures advanced fiber lasers for application in fundamental research, material processing, holography, image recording, printing, medicine, bioinstrumentation and others. Fiber lasers are reliable and high-powered with high beam quality, compact and adjustment-free design, no water cooling and other customer-friendly features. Inversion's product line includes high-power Argon/Krypton lasers generating in UV, blue-green, and yellow-red spectrum ranges (e.g. 1W 244 nm Ar laser for use in fiber Bragg grating technology). The company also produces fiber lasers in the infra-red and green spectrum ranges, including tuneable Yb-doped and Raman fiber lasers, single-frequency and frequency-doubled Yb-doped fiber lasers. Inversion is in the advanced development stage for various blue-green fiber lasers as a future alternative to noble-gas and DPSS lasers. Inversion's products are used in many research institutes and companies in Russia, Germany, China, South Korea, Canada, the United States, and other countries. Inversion is located in Novosibirsk, Russia.

About Tekhnoscan

TEKHNOSCAN JS Company develops and manufactures lasers and laser-related products for a variety of scientific, technological, medical, and other applications. Tekhnoscan's main products are tuneable Ti:Sapphire and dye lasers (single-frequency, frequency-stabilized, narrow-band, intracavity frequency-doubled, pulsed, femtosecond), direct-diode-pumped Yb:KGW lasers (femtosecond, picosecond, narrow-band), and specialized laser equipment (resonant frequency doublers, scanning interferometers, auto-correlators, laser power meters, etc.). Tekhnoscan laser products are used in numerous scientific and technological organizations in Russia, Germany, France, Switzerland, Japan, China, South Korea, Canada, the United States, and other countries. Tekhnosan is located in Novosibirsk, Russia. For more information visit: www.tekhnoscan.ru.

About Zecotek

Zecotek Medical Systems (TSX VENTURE:ZMS - News; FRANKFURT:W1I - News) is a bio-photonics technology company developing high-performance crystals, photo detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders.

This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For additional information on Zecotek Medical Systems and our technologies please see our website at www.zecotekmed.com.

If you would like to receive news from Zecotek in the future, please email ir@zecotek.com and mention "ZMS News" in the subject heading or visit the corporate website at www.zecotekmed.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.


Contact:

Michael Minder
Zecotek Medical Systems Inc.
CFO; VP Corporate Development
(604) 827-5203

Tim McNulty
Caliber Capital Partners
(778) 327-6678
Email: ir@zecotek.com
Website: www.zecotekmed.com
 

gleich hier! Kaufen, bald sind wir wieder auf 1,25€  

pari wäre 1,25€!  

http://biz.yahoo.com/ccn/070503/200705030388360001.html?.v=1  

Zecotek lands $800,000 (U.S.) contract in India

2007-05-03 18:28 ET - News Release

Mr. Michael Minder reports

ZECOTEK SUBSIDIARY ANNOUNCES US$800,000 LASER CONTRACT WITH GOVERNMENT OF INDIA

Zecotek Medical Systems Inc. has signed a purchase agreement with an agency of the government of India for over $800,000 (U.S.) worth of laser products and services. Under the agreement Tekhnoscan JS Company, whose product portfolio and intellectual property were recently acquired by Zecotek's subsidiary Zecotek Laser Systems Pte. Ltd., will supply lasers and consulting services. Tekhnoscan was selected from a group of world-leading laser developers which applied for the government of India contract. The delivery of laser products and consulting services will be concluded within Zecotek's fiscal year ending July 31, 2007, with all revenue flowing to Zecotek Laser Systems.

"This is significant sale by Tekhnoscan and Zecotek Laser Systems," said Dr. A.F. Zerrouk, chairman, president and chief executive officer of Zecotek Medical Systems. "This demonstrates the quality and competitiveness of our portfolio of cutting-edge laser technologies, products and world-class production facilities. The team from Tekhnoscan has made an immediate impact by adding their expertise in product development, manufacturing and sales to our own new designs, including our 456-nanometre, 488-nanometre lasers for biomedical applications and a new line of fiber lasers, which we anticipate to reach the market later this year."

Zecotek Laser Systems receives continuing revenues generated from the sale of Tekhnoscan's current and future laser products in development, including future revenue generated by existing or future intellectual property which may be created under the new structure.

We seek Safe Harbor.

                    §
 

 

 

nach News aus! Bin mal wieder dabei...  

http://biz.yahoo.com/ccn/070509/200705090389582001.html?.v=1  

,,Production of Zecotek's photon counters is expected to begin in Q2 of this calendar year with South East Asia's highly competitive microelectronics wafer fabricators.''

 

wollen wir mal hoffen, das es jetzt wieder richtig abgeht!!!  

Zecotek say its solid state detector beats the tubes

2007-05-09 18:46 ET - News Release

Mr. Tim Mcnulty reports

ZECOTEK'S NEW-GENERATION SOLID-STATE PHOTO DETECTORS DEMONSTRATE SUPERIOR PERFORMANCE TO EXISTING PHOTO MULTIPLIER TUBES

Zecotek Medical Systems Inc. has released test results for its new-generation solid state photo detector, designated the surface Micro-pixel Avalanche Photo Diode, which demonstrated superior performance to existing photo multiplier tubes. This newest generation of silicon-based photon counters offers the performance of PMTs in a compact and cost-effective solid state device.

"The testing completed by the University of Washington validates that our MAPD improves performance with significantly less cost associated with current PMTs in PET (positron emission tomography) and other detection applications," said Dr. A.F. Zerrouk, chairman, president and chief executive officer of Zecotek Medical Systems. "The test results also confirm Zecotek's clear lead in the development of this key enabling technology for next-generation medical and industrial imaging devices. Furthermore, this represents a significant milestone in our program to develop integrated PET-MRI products."

The conclusive test results demonstrate that Zecotek's MAPD, in combination with its patented LFS scintillation crystal, outperform current PMTs in critical imaging parameters. The testing was conducted by the University of Washington's Tom Lewellen, a leading authority on positron emission tomography.

"The combination of Zecotek's MAPD and LFS crystals resulted in an equal to or greater than overall signal gain and an improved energy resolution than our labs have been able to obtain with PMTs and standard commercial crystals," said Dr. Lewellen. "These superior capabilities will be fully utilized in the next-generation of PET-MRI scanner systems currently being developed in our laboratory."

The compact size of the MAPD is a key advantage as it will allow scanning devices to be manufactured with direct coupling of individual crystals to a single independent photo detector. A PET scanner can contain up to 40,000 individual crystals and the size of PMT is a limiting factor to overall performance. The direct coupling of MAPD to LFS crystals is extremely important to the future development of very high-resolution detector designs that have not been possible due to the inability of PMT devices to provide sensors on the fine pitch required and due to the cost of existing photo detector technologies. The use of MAPD array devices with very fine pitch is a cornerstone of the depth-of-interaction, high-spatial-resolution detectors for both preclinical stand-alone PET scanners and for PET-MRI systems.

Zecotek's solid state photon counters have been designed to offer significant cost and performance advantages over the current vacuum tube-based photo multiplier tubes. PMT-based photo-detection devices form a major cost component in the $1-billion (U.S.) market for PET and PET-CT scanners, representing approximately one-third of the cost of each unit. Existing PMTs are also key components of medical inspection devices used in blood analysis and DNA sequencing. Additional non-medical applications include: gamma ray detectors for homeland security, environmental monitoring, industrial control systems, robotics, biomedical testing, navigation and guidance systems, laser radars, and high-energy physics.

Production of Zecotek's photon counters is expected to begin in the second quarter of this calendar year with southeast Asia's highly competitive microelectronics wafer fabricators.

We seek Safe Harbor.  

Das geht heute hier so richtig ab!  

 

große Explosionsgefahr!! Tippe bis 20 Uhr auf mindestens 1,25€...  

1,25 Euro für heute 20 Uhr sind schon ein wenig hoch angesetzt!  

denn dann wäre ich auch endlich wieder im Plus ;-)))

Bin leider viel zu spät auf den Zug aufgesprungen, doch fest davon überzeugt, dass wir hier demnächst viel Freude dran haben werden!!!

Wenn die einmal losgelegt haben, wird die so leicht nichts mehr stoppen!!!

Die Erfindung spricht für sich.  

Sieh Dir die News an! Ich kenne Werte die sich nach solchen News verdoppelt haben...  

Nach vielen Jahren der Forschung scheint es so, als würde ZECOTEK nun die Früchte ernten.

Bei der Medical Image-Sparte läuft alles nach Plan. Die LFS werden von NG bereits produziert. Die Detektoren kommen nun dazu. Fehlen jetzt nur noch Aufträge durch GE, Siemens, etc. und das "Buffet" mit einem Marktpotential von 600 Mio.US$ ist eröffnet.

Der Verkauf von Laserprodukten an Indien ist für mich eine Überraschung. Zumal die Erlöse noch im 1.HJ an ZECOTEK fliessen werden. Dieser Deal dürfte nur der Anfang sein. Auch hier erwarte ich, dass sich ZECOTEK ein Stück des 2,5 Mrd. Marktpotential in der Lasersparte sichert.

Würde nur noch ein Vertragsabschluss in der 3D-Sparte mit dem Großkonzern fehlen.

Die Technologie von ZECOTEK ist sehr gut. Mit dem Newsflow in der letzten Zeit bin ich auch zufrieden. Vielleicht gelingt es ZECOTEK noch an einem anderen Börsensegment notiert zu werden (z.B. NASDAQ) und evtl. der Verkauf einer Sparte. Hier würde sich wohl die 3D-Sparte am ehesten anbieten?!? Ich denke das alles ist im Management evtl. bereits angedacht. Vielleicht klappt´s ja?

Wenn es weiterhin so gut läuft, dann könnte man durchaus einen ähnlichen Kursverlauf wie bei anderen erfolgreichen Unternehmen im Lasersektor sehen.

Warten wir mal ab. Momentan sieht es auf jeden Fall garnicht so schlecht aus, denke ich.

 

Zecotel Medical Systems, Frankfurt WKN A0JKHL, TSX Venture: ZMS, www.zecotekmed.com
Gestern nachbörslich gab das Unternehmen sensationelle News bekannt.
An der Uni Washington wurden wurden von Professor Lewellen, einer Koryphäe in der Medizintechnologie, Test durchgeführt, die bisherigen Erkenntnisse nicht nur bestätigten sondern sogar übertreffen.
Es ist nun wissenschaftlich bewiesen, das die Kombination "Zecotek LFS Kristall" + "Zecotek Photodetektor" den bisherigen, gebräuchlichen Lösungen haushoch überlegen ist. Aber das wichtigste ist wohl die wirtschaftliche Komponente, die da lautet: BILLIGER.
Lesen Sie hier die News im Original
Und dies ist eine Komponente, die im Branchenkampf der der Riesen, GE, Siemens und Phillips, dazu geschaffen ist, verlorene Marktanteile zurück zu gewinnen (GE), die Marktführerschaft auszubauen (Siemens) oder schnell Marktanteile an sich zu reißen (Phillips).
Für mich ist Zecotek DIE Story im Med-Tech Bereich, die nicht zu toppen ist. Sollten sie heute auf einen schnellen Trade aus sein, dann ist Zecotek sicherlich das falsche Papier. Kaufen Sie Zecotek wirklich nur, wen sie einen Anlagehorizont haben, der größer als 6 Monate ist. Sie können sich sicher sein, dass die Verantwortlichen bei den Marktführern diese Pressemitteilung sehr wohl registriert haben aber die Mühlen mahlen bei Branchenprimussen oft langsamer. Dennoch bin ich davon überzeugt, dass wir heuer noch einen großen Vertragsabschluß sehen werden.
Eine schüchterne Randbemerkung mit großer Bedeutung:
Production of Zecotek's photon counters is expected to begin in Q2 of this calendar year with South East Asia's highly competitive microelectronics wafer fabricators.
Mit der Produktion des Photodedektors wird schon im Sommer begonnen.
Ich habe mich diesbezüglich auch schlau gemacht. Ein derzeit gebräuchlicher Photodetektor kostet so um die 20 USD. Der Zecotek´sche Photonenzähler wird um die 7 USD kosten. Einnicht unbedeutender wirtschaftlicher Vorteil!
 

bullVestor - Zecotek-Story nicht zu toppen

14:39 10.05.07

St. Valentin (aktiencheck.de AG) - Nach Ansicht der Experten von "bullVestor" ist die Story der Zecotek-Aktie (ISIN CA9892131033/ WKN A0JKHL) nicht zu toppen.

Gestern nachbörslich habe das Unternehmen sensationelle News bekannt gegeben. An der Uni Washington seien von Professor Lewellen, einer Koryphäe in der Medizintechnologie, Tests durchgeführt worden, die die bisherigen Erkenntnisse nicht nur bestätigten sondern sogar übertreffen würden. Es sei nun wissenschaftlich bewiesen, das die Kombination "Zecotek LFS Kristall" + "Zecotek Photodetektor" den bisherigen, gebräuchlichen Lösungen haushoch überlegen sei. Aber das wichtigste sei wohl die wirtschaftliche Komponente, die da laute: "Billiger". Und dies sei eine Komponente, die im Branchenkampf der Riesen, GE, Siemens und Phillips, dazu geschaffen sei, verlorene Marktanteile zurück zu gewinnen (GE), die Marktführerschaft auszubauen (Siemens) oder schnell Marktanteile an sich zu reißen (Phillips).

Für die Wertpapierexperten sei Zecotek "die" Story im Med-Tech Bereich, die nicht zu toppen sei. Sollten Anleger heute auf einen schnellen Trade aus sein, dann sei Zecotek sicherlich das falsche Papier. Anleger sollten wirklich nur kaufen, wenn sie einen Anlagehorizont hätten, der größer als sechs Monate sei. Anleger könnten sich sicher sein, dass die Verantwortlichen bei den Marktführern diese Pressemitteilung sehr wohl registriert hätten aber die Mühlen würden bei Branchenprimussen oft langsamer mahlen. Dennoch seien die Wertpapierexperten davon überzeugt, dass man bald noch einen großen Vertragsabschluß sehen werde.

Eine schüchterne Randbemerkung mit großer Bedeutung: "Production of Zecotek's photon counters is expected to begin in Q2 of this calendar year with South East Asia's highly competitive microelectronics wafer fabricators." Mit der Produktion des Photodetektors werde schon im Sommer begonnen. Die Wertpapierexperten hätten sich diesbezüglich auch schlau gemacht. Ein derzeit gebräuchlicher Photodetektor koste so um die 20 USD. Der Zecotek'sche Photonenzähler werde um die 7 USD kosten. Ein nicht unbedeutender wirtschaftlicher Vorteil.

Nach Ansicht der Experten von "bullVestor" ist die Story der Zecotek-Aktie nicht zu toppen. (10.05.2007/ac/a/a)

 

Zecotek Medical Systems, Frankfurt WKN A0JKHL, TSX Venture: ZMS, www.zecotekmed.com
Vertrauen Sie mir! diese Aktie wird schon in absehbarer Zeit weitaus höher stehen als heute!

Herzliche Grüße
Ihr Helmut Pollinger
 

bullVestor - Zecotek Medical Systems "strong buy"  

12:19 18.05.07  

St. Valentin (aktiencheck.de AG) - Die Experten von "bullVestor" bewerten die Aktie von Zecotek Medical Systems (ISIN CA9892131033/ WKN A0JKHL) mit "strong buy".

Die Wertpapierexperten hätten am Mittwoch den Präsidenten und CEO von Zecotek getroffen. In dem vier Stunden dauernden Gespräch seien den Experten fast Ohren und Augen übergegangen. Die Wertpapierexperten würden noch auf die Freigabe der Infos warten, die man den Anlegern präsentieren werde.

Die Experten von "bullVestor" bewerten die Zecotek Medical Systems-Aktie mit "strong buy". (Ausgabe vom 18.05.07) (18.05.2007/ac/a/a)